Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968355 · ClinicalTrials.gov registry record
Clinical Evaluation of the FilmArray® Global Fever (GF) Panel
A clinical trial of Fever, sponsored by BioFire Defense.
- Completed
- Registry status
- 2,084
- Enrollment target
- 11
- Study locations
NCT02968355: Completed study of Fever, sponsored by BioFire Defense.
NCT02968355 is a study of Fever that has completed, run by BioFire Defense. The registered enrollment target is 2,084 participants, above the 484-participant average among 18 other Fever trials with a reported enrollment target (331% higher). The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02968355, a study of Fever, has completed, sponsored by BioFire Defense.
- COMPLETED
- Registry status
- 2,084 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will evaluate the clinical sensitivity and specificity of the FilmArray Global Fever (GF) Panel.
Primary Outcome
Percent Positive Agreement and Percent Negative Agreement between FilmArray Result and Comparator Assay
Conditions Studied
Interventions
- OTHER Observational study
Study Locations (11)
Other
- Naval Medical Research Unit Two - Phnom Penh
- United States Army Medical Research Directorate Georgia - Tbilisi
- Naval Medical Research Unit Three - Navrongo
- United States Army Medical Research Directorate Kenya - Kisumu
- Naval Medical Research Unit Six - Iquitos
- Kilimanjaro Christian Medical Centre - Moshi
- Armed Forces Research Institute of Medical Sciences - Bangkok
- Infectious Diseases Institute - Kampala
District of Columbia
- George Washington University - Washington D.C.
Missouri
- Washington University - St Louis
Central District
- Universidad Nacional Autonoma de Honduras - Tegucigalpa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,084 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2021-03-30 |
What the finished NCT02968355 record still lists
NCT02968355 is an observational study that tracks outcomes without assigning an intervention. Its 2,084 participants enrollment target places it among the larger protocols in the corpus, above the 484-participant average among 18 other Fever trials with a reported enrollment target (331% higher).
The record links to 1 condition, with Fever appearing as the primary indexed condition, and to 1 intervention - of which Observational study is the first listed.
NCT02968355 lists 11 locations in 4 states (Other, District of Columbia, Missouri).
Frequently Asked Questions
What is clinical trial NCT02968355 about?
NCT02968355 is a clinical study titled "Clinical Evaluation of the FilmArray® Global Fever (GF) Panel". This study will evaluate the clinical sensitivity and specificity of the FilmArray Global Fever (GF) Panel.
What is the current status of trial NCT02968355?
This trial is currently completed. The enrollment target is 2,084 participants. The study started on 2018-03-26. Estimated completion is 2021-03-30.
What conditions does trial NCT02968355 study?
This clinical trial studies the following conditions: Fever.
What interventions are being tested in trial NCT02968355?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT02968355?
This trial is sponsored by BioFire Defense, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02968355 being conducted?
This trial has 11 study locations across District of Columbia, Missouri, Central District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02968355's enrollment target sits among peer trials
2,084 2nd of 18 the highest of 18 other Fever trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fever trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
RECRUITING · NA
-
Remote Temperature Monitoring of Patients At Risk for Developing Fever
RECRUITING · NA
-
Prescription Antipyretics to Decrease Unscheduled Return Visits In A Pediatric Emergency Department
RECRUITING · NA
-
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
RECRUITING
-
Safety of RSV Preventive Monoclonal Antibody
RECRUITING · Phase 4
-
Tympanic Thermometer Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373564 · 2,076 participants · Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI